1. Smolen JS, Aletaha D, Bijlsma JW et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69 (4): 631–7.
2. Smolen JS, Landew é R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69 (6): 964–75.
3. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59 (6): 762–84.
4. Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: preva-lence, predictors, correlates, and outcomes. J Rheumatol 2007; 34 (4): 696–705.
5. Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheuma-toid arthritis – results of a prospective non-interventional study. Clin Rheumatol 2010; 29 (8): 913–20.
6. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheuma-toid arthritis. Lancet 1997; 350 (9074): 309–18.
7. Svensson B et al. Low-dose prednisolone in addition to the initial disease-modifying antir-heumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and in-creases the remission rate: a two-year randomized trial. Arthritis Rheum 2005; 52 (11): 3360–70.
8. Emery P, Breedveld F, van der Heijde D et al. Combination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial Group. Two-year clinical and radiographic results with combi-nation etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 2010; 62 (3): 674–82.
9. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52 (11): 3381–90.
10. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011; 70 (6): 1039–46.
11. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheu-matoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 17–23, 364 (9430): 263–9.
12. Cantini F, Nannini C, Niccoli L. Bioboosters in the treatment of rheumatic diseases: a com-prehensive review of currently available biologics in patients with rheumatoid arthritis, ankylos-ing spondylitis and psoriatic arthritis. Open Access Rheumatology: Research and Reviews 2009; 1: 163–78.
13. Kalden JR, Nüsslein HG, Wollenhaupt J et al. Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clin-ical trial. Clin Exp Rheumatol 2008; 26 (5): 834–40.
14. De Stefano R, Frati E, Nargi F et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol 2010; 29 (5): 517–24.
15. Strangfeld A, Hierse F, Kekow J et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 2009; 68 (12): 1856–62.
16. Wendler J, Soerensen H, Tony H et al. Effectiveness and safety of rituximab (RTX)-monotherapy compared to RTX-combination therapy with methotrexate (MTX) or leflunomide (LEF) in the German RTX treatment of active rheumatoid arthritis (RA) in daily practice trial. Ann Rheum Dis 2009; 68 (Suppl. 3): 76.
17. Насонов Е.Л., Лукина Г.В., Сигидин Я.А. Комбинированная терапия ритуксимабом и лефлуномидом при ревматоидном артрите (предварительные результаты российского регистра АРБИТР). Научно-практическая ревматология. 2011; 1: 16–20.
18. Gabay C et al. Effectiveness of different DMARD co-therapies in rituximab-treated rheuma-toid arthritis (RA) patients – results of a one-year follow up study from the CERRERA collabo-ration Ann Rheum Dis 2010; 69 (Suppl. 3): 68.

Ю.А.Олюнин
 
НИИ ревматологии РАМН, Москва